Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Frontline Ribociclib/Endocrine Therapy Generates Similar ORR to Combination Chemo in HR+/HER2– Advanced Breast Cancer

February 27th 2023

Yen-Shen Lu, MD, PhD, discusses the primary results of the RIGHT Choice trial and what they could mean for the use of ribociclib and endocrine therapy in this population.

Second-Line Treatment of HER2+ mBC and Recent Data Updates

February 27th 2023

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Options for Third- and Further-Line Treatment of HER2+ mBC

February 27th 2023

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

Dr. McArthur on the Implications of the ASCENT Trial in TNBC

February 24th 2023

Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.

Bria-IMT Plus Retifanlimab Continues to Show Early Clinical Benefit in Advanced Metastatic Breast Cancer

February 23rd 2023

The combination of the targeted immunotherapy Bria-IMT and retifanlimab demonstrated signs of clinical benefit and was found to be well tolerated in patients with advanced metastatic breast cancer.

Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

February 23rd 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Dr. Kaklamani on Racial Disparities and Clinical Outcomes in the RxPONDER Trial in Breast Cancer

February 22nd 2023

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

Dr. Blackwood on the Implementation of the I SPY2 Trial in Breast Cancer

February 22nd 2023

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

The Role of ADCs in the Treatment of TNBC

February 22nd 2023

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)

February 22nd 2023

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

Aileron Terminates Phase 1b Trial Evaluating ALRN-6924 in P53-mutant Breast Cancer

February 22nd 2023

Despite treatment with the chemoprotective agent ALRN-6924, patients with p53-mutated breast cancer receiving neoadjuvant or adjuvant therapy with docetaxel, doxorubicin, and cyclophosphamide failed to meet the trial’s primary and secondary end points of duration and incidence of severe neutropenia in cycle 1 and incidence of chemotherapy-induced alopecia, respectively.

Toripalimab Plus Chemotherapy Meets PFS End Point in PD-L1+ TNBC

February 21st 2023

Toripalimab plus nab-paclitaxel demonstrated a significant improvement in progression-free survival compared with placebo and nab-paclitaxel in PD-L1–positive patients with stage IV or recurrent/metastatic triple-negative breast cancer.

Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

February 21st 2023

The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.

HER2+ mBC: First-Line Treatment Regimens

February 21st 2023

A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.

Expert Perspectives on Defining HER2-Low Breast Cancer

February 21st 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Overview on Treatment Options for HER2+ Breast Cancer

February 21st 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

Sacituzumab Govitecan Represents Improved Later-line Option Vs Chemotherapy in Metastatic HR+/HER2– Breast Cancer

February 20th 2023

Tiffany A. Traina, MD, discusses the significance of the FDA approval of sacituzumab govitecan for patients with metastatic hormone receptor-positive, HER2-negative breast cancer and expanded on the data from TROPiCS-02 that supported the approval.

Therapeutic Advances Rapidly Expand the Breast Cancer Armamentarium Across Subtypes

February 20th 2023

An increasing focus on antibody-drug conjugates for HER2-positive breast cancer signals a potential shift in the standard of care for this population.

Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast Cancer

February 16th 2023

Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.